The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Efficacy and safety of rivaroxaban versus apixaban for venous thromboembolism: A systematic review and meta-analysis of observational studies
Abstract
Background Direct-acting oral anticoagulants (DOACs) including rivaroxaban and apixaban are preferred over vitamin K antagonists for the treatment of venous thromboembolism (VTE). We conducted a systematic review and a meta-analysis to compare the efficacy and safety of rivaroxaban versus apixaban in the treatment of VTE. Methods We conducted an electronic search for studies that directly compared treatment with rivaroxaban and apixaban in adult patients with VTE. The relative risks (RRs) and 95% confidence intervals (CIs) were estimated and pooled using a fixed-effect model unless significant heterogeneity was present (I 2 > 40%), then random-effects model was used. The primary efficacy and safety outcomes were recurrent VTE (rVTE) and major bleeding events, respectively. Results Nine observational studies were included in our meta-analysis, assessing 24,156 patients for apixaban and 38,847 for rivaroxaban. Pooling of data for our primary efficacy outcome showed a trend towards lower risk of rVTE with apixaban compared to rivaroxaban (RR 0.77, 95% CI 0.57-1.04, I 2 = 53%). Analysis of our primary safety outcome showed a significantly lower risk of major bleeding with apixaban compared to rivaroxaban (RR 0.68, 95% CI 0.61-0.76, I 2 = 0%). Apixaban was associated with significantly decreased risk of net clinical harm, clinically relevant non major bleeding (CRNMB) and any bleeding, compared to rivaroxaban (RR 0.75, 95% CI 0.61-0.92, I 2 = 50%; RR 0.58, 95% CI 0.50-0.67, I 2 =…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions
Sterne, J. A., Hernán, M. A., Reeves, B. C., Savović, J., Berkman, N. D., Viswanathan, M., Henry, D., Altman, D. G., Ansari, M. T., Boutron, I., et al. (2016) · BMJ · doi:10.1136/bmj.i4919 · Cited by 20,329
Heart Disease and Stroke Statistics—2010 Update: A Report From the American Heart Association
WRITING GROUP MEMBERS, Lloyd-Jones, D., Adams, R. J., Brown, T. M., Carnethon, M., Dai, S., De Simone, G., Ferguson, T. B., Ford, E., Furie, K., et al. (2010) · Circulation · doi:10.1161/circulationaha.109.192667 · Cited by 5,700
SCHULMAN, S., & KEARON, C. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01204.x · Cited by 5,009
Konstantinides, S. V., Meyer, G., Becattini, C., Bueno, H., Geersing, G.-J., Harjola, V.-P., Huisman, M. V., Humbert, M., Jennings, C. S., Jiménez, D., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz405 · Cited by 4,916
Antithrombotic Therapy for VTE Disease
Kearon, C., Akl, E. A., Ornelas, J., Blaivas, A., Jimenez, D., Bounameaux, H., Huisman, M., King, C. S., Morris, T. A., Sood, N., et al. (2016) · Chest · doi:10.1016/j.chest.2015.11.026 · Cited by 4,830
Oral Rivaroxaban for Symptomatic Venous Thromboembolism
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1007903 · Cited by 3,237
Oral Apixaban for the Treatment of Acute Venous Thromboembolism
Agnelli, G., Buller, H. R., Cohen, A., Curto, M., Gallus, A. S., Johnson, M., Masiukiewicz, U., Pak, R., Thompson, J., Raskob, G. E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302507 · Cited by 2,324
Prandoni, P., Lensing, A. W. A., Piccioli, A., Bernardi, E., Simioni, P., Girolami, B., Marchiori, A., Sabbion, P., Prins, M. H., Noventa, F., et al. (2002) · Blood · doi:10.1182/blood-2002-01-0108 · Cited by 1,863
Key, N. S., Khorana, A. A., Kuderer, N. M., Bohlke, K., Lee, A. Y. Y., Arcelus, J. I., Wong, S. L., Balaban, E. P., Flowers, C. R., Francis, C. W., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.01461 · Cited by 1,504
Ortel, T. L., Neumann, I., Ageno, W., Beyth, R., Clark, N. P., Cuker, A., Hutten, B. A., Jaff, M. R., Manja, V., Schulman, S., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020001830 · Cited by 1,489 · cited 2×
“The American Society of Hematology (ASH) 2020 guidelines for management of VTE also suggest using DOACs over VKA [8].”
Research works printed but not linked: 1
- Higgins JPT, Cochrane Collaboration (2020) Cochrane handbook for systematic reviews of interventions, 2nd edn. Wiley-Blackwell, Hoboken
Cited by
Roupe, M., Rosengren, A., Pivodic, A., Bertilsson, R., Philipson, J., Svennerholm, K., Tavoly, M., & Sandblad, K. G. (2025) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2025.106438 · Cited by 8
Bleeding Risk with Apixaban vs. Rivaroxaban in Acute Venous Thromboembolism
Castellucci, L. A., Gal, G. L., & Rodger, M. (2026) · New England Journal of Medicine · doi:10.1056/nejmc2604760 · Cited by 2
Rivaroxaban Versus Apixaban: A Comparison Without a Simple Solution
Cohen, M. C., Spyropoulos, A. C., Goodman, S. G., Spinler, S. A., Bonaca, M. P., Redling, T. M., Visveswaran, G. K., & Sohal, S. (2024) · Mayo Clinic Proceedings Innovations Quality & Outcomes · doi:10.1016/j.mayocpiqo.2024.05.004 · Cited by 3
Almutairi, A. R., AlRuthia, Y. S., Yami, M. S. A., Alshaya, O. A., Alanazi, T. D. M., Daghreer, S. I. A., Korayem, G. B., Al-Rasheed, S. A., Alorf, R. A., & Almohammed, O. A. (2025) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/10760296251318705 · Cited by 1
Elbadr, M. M., Galal, H. A., Hetta, H. F., Elfadil, H., Alanazi, F. E., Fawzy, S., Aljohani, H. M., Ellah, N. H. A., Ali, M. F., Dyab, A. K., et al. (2025) · Diseases · doi:10.3390/diseases13030087 · Cited by 2
Metadata
- Authors
- Fredman, D., McNeil, R., Eldar, O., Leader, A., Gafter-Gvili, A., & Avni, T.
- Affiliations
- Tel Aviv University (IL)
- Corresponding author
- Fredman, Danielle
- Venue
- Journal of Thrombosis and Thrombolysis
- Published
- 2023-12-21
- Volume
- 57
- Issue
- 3
- Pages
- 453-465
- ISSN
- 0929-5305 (ISSN-L)
- 1573-742X
- OpenAlex
- W4390049377
- Cited by
- 21
- References
- 32
- Citations by year
- 2026: 11 · 2025: 6 · 2024: 4
- FWCI
- 1.47
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Journal of Thrombosis and Thrombolysis (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Keywords
- rivaroxaban, apixaban, venous thromboembolism, direct oral anticoagulants, recurrent venous thromboembolism, major bleeding, clinically relevant non-major bleeding, anticoagulant safety, anticoagulant efficacy
- MeSH terms
- Rivaroxaban, Hemorrhage, Humans, Pyrazoles, Pyridones, Treatment Outcome, Venous Thromboembolism, Observational Studies as Topic, Factor Xa Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy and safety of rivaroxaban versus apixaban for venous thromboembolism: A systematic review and meta-analysis of observational studies. https://app.cochat.ai/papers/10.1007/s11239-023-02926-3
- The paper
- Fredman, D., McNeil, R., Eldar, O., Leader, A., Gafter-Gvili, A., & Avni, T. (2023). Efficacy and safety of rivaroxaban versus apixaban for venous thromboembolism: A systematic review and meta-analysis of observational studies. Journal of Thrombosis and Thrombolysis. https://doi.org/10.1007/s11239-023-02926-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.